<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04217291</url>
  </required_header>
  <id_info>
    <org_study_id>SY004003</org_study_id>
    <nct_id>NCT04217291</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Different Doses of SY-004 in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>Evaluation of the Efficacy and Safety of Different Doses of SY-004 in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Yabao Pharmaceutical R&amp;D Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Yabao Pharmaceutical R&amp;D Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study&#xD;
      in patients with type 2 diabetes mellitus (T2DM).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      200 cases will be included and divided into four groups with 50 cases in each group&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Glycosylated Hemoglobin A1c (HbA1c)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Changes in Glycosylated Hemoglobin A1c relative to baseline at 16 weeks compared to placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the proportion of subjects whose Glycosylated Hemoglobin A1c (HbA1c) was less than 7%.</measure>
    <time_frame>16 weeks</time_frame>
    <description>At the end of 16 weeks, the proportion of subjects whose Glycosylated Hemoglobin A1c was less than 7% .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with Glycosylated Hemoglobin A1c (HbA1c) &lt; 6.5%</measure>
    <time_frame>16 weeks</time_frame>
    <description>The proportion of subjects with Glycosylated Hemoglobin A1c &lt; 6.5% at 16 weeks after administration of SY-004.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Glycosylated Hemoglobin A1c (HbA1c)</measure>
    <time_frame>8 weeks</time_frame>
    <description>The change of Glycosylated Hemoglobin A1c relative to the baseline after 8 weeks of treatment with SY-004.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the proportion of subjects whose Glycosylated Hemoglobin A1c (HbA1c) was less than 7%</measure>
    <time_frame>8 weeks</time_frame>
    <description>At the end of 8 weeks, the proportion of subjects whose Glycosylated Hemoglobin A1c was less than 7% .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with Glycosylated Hemoglobin A1c (HbA1c) &lt; 6.5%</measure>
    <time_frame>8 weeks</time_frame>
    <description>The proportion of subjects with Glycosylated Hemoglobin A1c &lt; 6.5% at the end of 8 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting blood glucose (FPG) relative to the baseline</measure>
    <time_frame>1、2、4、8、12、16weeks</time_frame>
    <description>Changes in fasting blood glucose (FPG) relative to the baseline at 1, 2, 4, 8, 12 and 16 weeks after administration of SY-004.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in postprandial blood glucose auc0-2h</measure>
    <time_frame>16 weeks</time_frame>
    <description>Changes in postprandial blood glucose auc0-2h ( 0-2h blood glucose AUC of Mixed-Meal-Tolerance-Test ) relative to baseline at 16 weeks after administration of SY-004.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in abdominal weight relative to baseline at 8 and 16 weeks.</measure>
    <time_frame>8、16weeks</time_frame>
    <description>Changes in abdominal weight relative to baseline at 8 and 16 weeks after administration of SY-004.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>SY-004-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a dose of 80mg/day taken orally for two weeks, and a dose of 80mg/day for 14 weeks from the third week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SY-004-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a dose of 80mg/day taken orally for two weeks, and a dose of 160mg/day for 14 weeks from the third week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SY-004-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a dose of 80mg/day orally in the first week, a dose of 160mg/day in the second week and a dose of 240mg/day for 14 weeks from the third week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>a dose of SY-004 matching placebo taken orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SY-004</intervention_name>
    <description>Take orally once a day</description>
    <arm_group_label>SY-004-1</arm_group_label>
    <arm_group_label>SY-004-2</arm_group_label>
    <arm_group_label>SY-004-3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SY-004 matching placebo</intervention_name>
    <description>Take orally once a day</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Gender is not limited.&#xD;
&#xD;
          -  Age at screening: ≥ 18 years old, ≥ 75 years old.&#xD;
&#xD;
          -  According to WHO diagnostic criteria and classification in 1999, type 2 diabetes was&#xD;
             diagnosed, with a course of at least 3 months.&#xD;
&#xD;
          -  During screening and before randomization, 18kg / m2 ≤ BMI ≤ 35kg / m2.&#xD;
&#xD;
          -  At the time of screening, they had been treated with diet or exercise for at least 3&#xD;
             months.&#xD;
&#xD;
          -  No antidiabetic drugs were used at the time of screening, or the antidiabetic drugs&#xD;
             were used irregularly within 3 months before screening (the cumulative use of&#xD;
             antidiabetic drugs in the past 3 months was no more than 2 weeks and no antidiabetic&#xD;
             drugs were used in the past 1 month).&#xD;
&#xD;
          -  During screening, 7% of the samples detected by local laboratory were ≤ HbA1c ≤ 11%.&#xD;
&#xD;
          -  Before randomization, the central laboratory tested 7% ≤ HbA1c ≤ 11%.&#xD;
&#xD;
          -  Fasting blood glucose (FBG) of 7-13.3 mmol / L (including boundary value) was measured&#xD;
             in the central laboratory before randomization.&#xD;
&#xD;
          -  The subjects must have informed consent before the study, and signed the written&#xD;
             informed consent voluntarily.&#xD;
&#xD;
          -  The subjects were willing and able to use the home blood glucose meter for self blood&#xD;
             glucose monitoring.&#xD;
&#xD;
          -  The subjects were able to communicate well with the researchers and complete the study&#xD;
             according to the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Staff members and their immediate family members of the research project. Lineal&#xD;
             relatives refer to persons with consanguineous or legal relationships, including&#xD;
             spouses, parents, children, brothers and sisters.&#xD;
&#xD;
          -  Any of the following drugs or treatments were used prior to screening:&#xD;
&#xD;
               1. In the past six months, insulin therapy has been used for more than one month, or&#xD;
                  insulin therapy is needed at present.&#xD;
&#xD;
               2. Long acting GLP-1 has been used in the past 6 months.&#xD;
&#xD;
               3. Glucokinase activator (GKA) was used in the past 6 months.&#xD;
&#xD;
               4. In the past 6 months, I have received weight-loss drugs or any weight-loss&#xD;
                  treatment (such as surgery, excessive diet and exercise therapy) that leads to&#xD;
                  weight instability.&#xD;
&#xD;
               5. Participated in clinical trials of any drug or medical device in the past 3&#xD;
                  months.&#xD;
&#xD;
               6. Other drugs that may affect blood glucose metabolism have been used in the past 8&#xD;
                  weeks, including growth hormone treatment, and long-term or repeated intermittent&#xD;
                  systemic glucocorticoids (intravenous, oral or intra-articular administration for&#xD;
                  more than 2 weeks or repeated courses, except inhalation or local external use),&#xD;
                  etc.&#xD;
&#xD;
               7. Strong CYP3A inducers or strong CYP3A inhibitors have been used in the past two&#xD;
                  weeks or are planned to be used in the near future (refer to appendix 12.5.1).&#xD;
&#xD;
               8. Drugs that are likely to cause torsade de pointes have been used in the past two&#xD;
                  weeks or planned in the near future (refer to appendix 12.5.2).&#xD;
&#xD;
          -  Prior to screening, there was a history or evidence of any of the following diseases:&#xD;
&#xD;
               1. Type 1 diabetes, special type diabetes and secondary diabetes.&#xD;
&#xD;
               2. Significant clinical cardiovascular events have occurred in the past 6 months&#xD;
                  (refer to appendix 12.3).&#xD;
&#xD;
               3. Patients with clinically significant peripheral vascular lesions, such as&#xD;
                  ischemic ulcer or gangrene, diabetic foot ulcer and infection.&#xD;
&#xD;
               4. There is sufficient evidence for the presence of active diabetic proliferative&#xD;
                  retinopathy or maculopathy that is unstable or in need of treatment.&#xD;
&#xD;
               5. there are obvious autonomic neuropathy, such as urinary retention, orthostatic&#xD;
                  hypotension, diabetic diarrhea or gastroparesis.&#xD;
&#xD;
               6. Have a history of acute or chronic pancreatitis.&#xD;
&#xD;
               7. Ketoacidosis, diabetic acidosis or hyperosmolar nonketotic coma have occurred in&#xD;
                  the past 6 months and need to be hospitalized.&#xD;
&#xD;
               8. In the past 6 months, serious hypoglycemic events with unknown causes (need other&#xD;
                  people's help to recover); or frequent hypoglycemia: for example, more than two&#xD;
                  hypoglycemic events (blood glucose ≤ 3.9mmol / L) occurred in the first month&#xD;
                  before screening.&#xD;
&#xD;
               9. Any endocrine system disease related to blood glucose (such as hyperthyroidism,&#xD;
                  acromegaly, Cushing's syndrome), immune system disease or other diseases that are&#xD;
                  unstable or need treatment are not suitable for the study according to the&#xD;
                  judgment of researchers.&#xD;
&#xD;
              10. Have other diseases that affect glucose metabolism or are taking drugs that&#xD;
                  significantly affect glucose metabolism.&#xD;
&#xD;
              11. Severe trauma or acute infection that may affect blood glucose control has&#xD;
                  occurred in the past month.&#xD;
&#xD;
              12. Suffer from serious cardiovascular disease, respiratory system disease,&#xD;
                  gastrointestinal disease, liver dysfunction, renal dysfunction, endocrine disease&#xD;
                  (except diabetes), blood system disease, nervous system disease, and the disease&#xD;
                  status can significantly change the absorption, distribution, metabolism and&#xD;
                  excretion of the test drug, or taking the test drug will increase the risk of the&#xD;
                  subject or affect the analysis of the research results.&#xD;
&#xD;
              13. There are any types of malignant tumors (whether cured or not).&#xD;
&#xD;
              14. A history of diseases that may cause hemolysis or red blood cell instability that&#xD;
                  affect HbA1c detection, such as hemoglobinopathy (such as sickle cell anemia or&#xD;
                  thalassemia, ferriblastic anemia).&#xD;
&#xD;
              15. History of alcohol and drug abuse. Drink more than 21 units (male) or 14 units&#xD;
                  (female) of alcohol per week (1 unit is about 360 ml of beer or 45 ml of spirits&#xD;
                  or 150 ml of wine with 40% alcohol).&#xD;
&#xD;
              16. There are mental or nervous system diseases, unwillingness to communicate or&#xD;
                  language barriers, and insufficient understanding and cooperation.&#xD;
&#xD;
          -  There is any laboratory inspection index meeting the following standards at screening&#xD;
             or random:&#xD;
&#xD;
               1. In the absence of pacemaker, 12 lead ECG showed second or third degree&#xD;
                  atrioventricular block, or corrected qtcb &gt; 450ms (male) or &gt; 470ms (female).&#xD;
&#xD;
               2. eGFR&lt;60ml/(min•1.73m2)。&#xD;
&#xD;
               3. ALT &gt; 1.5 times the upper limit of normal value (× ULN), AST &gt; 1.5 × ULN, TBIL &gt;&#xD;
                  1.5 × ULN.&#xD;
&#xD;
               4. Hypertension (systolic blood pressure ≥ 160mmhg or diastolic blood pressure ≥&#xD;
                  100mmhg) that cannot be controlled by drugs or other treatment means exists.&#xD;
&#xD;
               5. Hypertriglyceridemia (triglyceride &gt; 500mg / dl (5.70mmol / L)) was found which&#xD;
                  could not be controlled by drugs or other treatments.&#xD;
&#xD;
               6. Hemoglobin &lt; 90g / L.&#xD;
&#xD;
               7. The serological evidence of infectious virus is positive, including hepatitis B,&#xD;
                  hepatitis C, HIV and Treponema pallidum.&#xD;
&#xD;
               8. Fasting C-peptide &lt; 1.0 ng / ml (333 pmol / L).&#xD;
&#xD;
          -  Fertile eligible subjects (men and women) disagreed with the use of reliable&#xD;
             contraceptive methods during the study and at least one month after the last&#xD;
             administration.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Allergic to the active ingredient agratine hydrochloride, or severe allergic&#xD;
             constitution / severe allergic history.&#xD;
&#xD;
          -  Other circumstances judged by the sponsor or researcher as unsuitable for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese PLA General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yiming Mu, Dr.</last_name>
    <phone>010-55499001</phone>
    <email>muyiming@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yiming Mu, Dr.</last_name>
      <phone>010-55499001</phone>
      <email>muyiming@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 30, 2019</study_first_submitted>
  <study_first_submitted_qc>January 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2020</study_first_posted>
  <last_update_submitted>May 15, 2021</last_update_submitted>
  <last_update_submitted_qc>May 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

